THE Therapeutic Goods Administration (TGA) has issued a new Medicines Safety Update, with the bulletin detailing potential issues around Viekira PAK, ingenol mebutate and testosterone.
Health professionals are advised that while the Product Information (PI) for hepatitis C drugs Viekira PAK and Viekira PAK-RBV carry a precaution for a potential interaction with ethinyloestradiol-containing medicines and use of these medicines is listed as a contraindication, not all ethinyloeastradiol-containing medicines currently provide similar information about Viekira PAK and Viekira PAK-RBV.
Technivie, a recently registered hepatitis C medicine, is also affected by this issue.
Other items in the update include warnings about hypersensitivity reactions, herpes zoster and eye injury which have been added to the PI for ingenol mebutate, marketed in Australia as Picato gel for the treatment of actinic keratosis.
There's also advice following a TGA review of testosterone and the risk of venous thromboembolism - see the update at tga.gov.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 22 May 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 22 May 17